- Home
- TGTX vs WTM Comparison
TGTX vs WTM Comparison
Compare TGTX & WTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TGTX
- WTM
- Stock Information
- Founded
- TGTX 1993
- WTM 1980
- Country
- TGTX United States
- WTM Bermuda
- Employees
- TGTX N/A
- WTM N/A
- Industry
- TGTX Biotechnology: Pharmaceutical Preparations
- WTM Property-Casualty Insurers
- Sector
- TGTX Health Care
- WTM Finance
- Exchange
- TGTX Nasdaq
- WTM Nasdaq
- Market Cap
- TGTX 5.5B
- WTM 4.4B
- IPO Year
- TGTX 1995
- WTM N/A
- Fundamental
- Price
- TGTX $32.18
- WTM $1,902.36
- Analyst Decision
- TGTX Strong Buy
- WTM
- Analyst Count
- TGTX 5
- WTM 0
- Target Price
- TGTX $48.20
- WTM N/A
- AVG Volume (30 Days)
- TGTX 1.8M
- WTM 26.7K
- Earning Date
- TGTX 11-03-2025
- WTM 11-06-2025
- Dividend Yield
- TGTX N/A
- WTM 0.05%
- EPS Growth
- TGTX N/A
- WTM N/A
- EPS
- TGTX 2.78
- WTM 54.05
- Revenue
- TGTX $531,898,000.00
- WTM $2,489,200,000.00
- Revenue This Year
- TGTX $82.31
- WTM N/A
- Revenue Next Year
- TGTX $49.05
- WTM N/A
- P/E Ratio
- TGTX $11.61
- WTM $35.01
- Revenue Growth
- TGTX 100.88
- WTM N/A
- 52 Week Low
- TGTX $25.28
- WTM $1,648.00
- 52 Week High
- TGTX $46.48
- WTM $2,023.00
- Technical
- Relative Strength Index (RSI)
- TGTX 39.20
- WTM 54.07
- Support Level
- TGTX $31.07
- WTM $1,888.00
- Resistance Level
- TGTX $34.74
- WTM $1,929.20
- Average True Range (ATR)
- TGTX 1.70
- WTM 32.84
- MACD
- TGTX -0.27
- WTM -6.85
- Stochastic Oscillator
- TGTX 17.74
- WTM 41.20
About TGTX TG Therapeutics Inc.
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.
About WTM White Mountains Insurance Group Ltd.
White Mountains Insurance Group Ltd is engaged in the business of making opportunistic and value-oriented acquisitions of businesses and assets in the insurance, financial services, and related sectors, operating these businesses and assets through its subsidiaries and, if and when attractive exit valuations become available, disposing of these businesses and assets. The company conducts its business in five areas: property and casualty insurance and reinsurance, municipal bond reinsurance, capital solutions for asset and wealth management firms, property and casualty insurance distribution, and other operations.